Transcat (TRNS) Q2 2027 Earnings Call Transcript
Transcat (TRNS) reported Q2 2027 revenue of $97.1M, up 18%, with service revenue growing 23% and distribution revenue up 10%. Gross profit increased 22%, and adjusted EBITDA grew 23% to $14.9M. The company cited strong demand in regulated end markets and strategic acquisitions, including Southeastern Biomedical Associates, as drivers of growth. Service gross margins expanded 220 basis points to 34.4%.
How this was made
The 30-second read
Why it matters
The disclosed quarter metrics (revenue, gross profit, adjusted EBITDA, EPS, and segment margins) and the Southeastern Biomedical Associates acquisition provide concrete inputs for updating near-term expectations for growth and profitability.
Market read
Traders can update valuation and positioning based on the quarter’s quantified beats and the acquisition-backed growth narrative.
What to watch
The excerpt ends mid-sentence on operating free cash flow, so full cash conversion, guidance details, and any risk commentary are not visible here; those could materially change the earnings interpretation.
Background
The transcript describes Transcat’s fiscal second quarter 2027 performance, emphasizing service growth, margin expansion, and continued M&A execution.
Ticker impact
Transcat reports fiscal Q2 2027 results with revenue up 18% to $97.1M, adjusted EBITDA up 23%, and EPS up 79%, plus margin expansion.
Likely upward bias as investors price in sustained service momentum and improving profitability, with acquisition execution as the key swing factor.
The article provides multiple quantified performance metrics (revenue, EBITDA, EPS, margins) and a specific acquisition update, which are direct inputs to near-term valuation and expectations.
Market effects
Reinforces demand strength in regulated calibration end markets (life sciences, aerospace and defense, energy) and the profitability potential of service mix.
Southeastern Biomedical Associates expands Transcat’s geographic footprint in the southeastern U.S., potentially improving regional customer coverage.
Limited direct global spillover; primarily impacts regulated services and calibration supply chains.
Counterpoint
Distribution margins are described as declining year-over-year due to lower-margin used equipment sales, which could cap consolidated margin upside if service growth slows.
Key entities
- companyTranscat
Reports fiscal Q2 2027 results and discusses service-led growth, margin expansion, and the Southeastern Biomedical Associates acquisition.
- acquired_companySoutheastern Biomedical Associates
August acquisition referenced as expanding Transcat’s biomedical calibration scale and geography in regulated end markets.
